Abstract Patient-Derived Xenografts (PDX) are powerful models to study tumors' drug-response in the context of personalized medicine. In the PDX model settings, by virtue of expanding the patient's tumor sample, testing multiple drug or drug-combinations can be executed rapidly and has no ethical limitations. However, there are major issues around standards that need to be addressed to make these models widely accessible and usable. The overarching goal of the PDXNet is to coordinate the development of appropriate PDX models and methods for preclinical drug testing to advance CTEP clinical development of new cancer agents. In an effort to standardize protocols for PDX generation as well as data analysis and metadata harmonization, we are building a data storage, sharing, and analysis platform that harmonizes PDXNet data with other large datasets and analysis workflows. The PDX Data Commons is built on top of existing NCI resources, leveraging the Cancer Genomics Cloud maintained by Seven Bridges Genomics, where PDXNet data is co-located with TCGA and other large-scale datasets. The PDCCC is co-led by experts from The Jackson Laboratory, providing scientific leadership in xenograft methods and cancer biology to ensure the promulgation of standards that are well-suited for the PDX community. In addition, the PDCCC is responsible for establishing studies to identify best-practices for PDX data analysis and metadata schemas. The data collected as part of the PDXNet is currently stored on the PDXNet portal that has a query interface for identifying models for pre-clinical trials. Simultaneously, we administer training activities and research pilots to build synergies within the PDXNet, enhancing the ability of the PDXNet to develop clinical trials from PDX studies. In PDXNet, besides the PDCCC, there are 4 PDX Development and Trial Centers (PDTCs) responsible for executing specific pre-clinical trials focused around cancer types including breast cancer, melanoma, and lung cancer. Data generated by the PDTCs will be hosted by the PDCCC, and metadata will be collected based on schemas developed by the network for systematic ontological analysis. These PDX models, in coordination with the NCI Patient-Derived Models Repository (PDMR) at the Frederick National Laboratory for Cancer Research (FNLCR) will be shared with the broader community. In addition, PDTC's will collaborate with non-PDXNet investigators for PDX studies through an administrative supplement program supported by the NCI. The PDXNet is a strong step toward building a consensus around PDX models, so that the power for discovery can be expanded by making multi-institutional PDX cohorts a reality. The PDCCC is a central part of this process to systematically capture and analyze the variables most influential to PDX models and share protocols and tools to make PDXs an interchangeable research currency for pre-clinical discovery. Citation Format: Anurag Sethi, Anuj Srivastava, Xingyi Woo, Vishal Sarsani, Ziming Zhao, Javad Noorbakhsh, Christian French, Jack DiGiovanna, Ogan D. Abaan, Steve Neuhauser, Peter Robinson, Yvonne A. Evrard, Carol J. Bult, Jeffrey A. Moscow, Brandi Davis-Dusenbery, Jeffrey H. Chuang. The PDX Data Commons and Coordinating Center (PDCCC) for PDXNet [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1029.